121 related articles for article (PubMed ID: 32561392)
1. The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound.
Bouwman SA; Zoleko-Manego R; Renner KC; Schmitt EK; Mombo-Ngoma G; Grobusch MP
Travel Med Infect Dis; 2020; 36():101765. PubMed ID: 32561392
[TBL] [Abstract][Full Text] [Related]
2. Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4.
Turner H
Future Med Chem; 2016; 8(2):227-38. PubMed ID: 26824174
[TBL] [Abstract][Full Text] [Related]
3. Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa.
Ndayisaba G; Yeka A; Asante KP; Grobusch MP; Karita E; Mugerwa H; Asiimwe S; Oduro A; Fofana B; Doumbia S; Jain JP; Barsainya S; Kullak-Ublick GA; Su G; Schmitt EK; Csermak K; Gandhi P; Hughes D
Malar J; 2021 Dec; 20(1):478. PubMed ID: 34930267
[TBL] [Abstract][Full Text] [Related]
4. Spiroindolone KAE609 for falciparum and vivax malaria.
White NJ; Pukrittayakamee S; Phyo AP; Rueangweerayut R; Nosten F; Jittamala P; Jeeyapant A; Jain JP; Lefèvre G; Li R; Magnusson B; Diagana TT; Leong FJ
N Engl J Med; 2014 Jul; 371(5):403-10. PubMed ID: 25075833
[TBL] [Abstract][Full Text] [Related]
5. Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria.
Hien TT; White NJ; Thuy-Nhien NT; Hoa NT; Thuan PD; Tarning J; Nosten F; Magnusson B; Jain JP; Hamed K
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872070
[TBL] [Abstract][Full Text] [Related]
6. Assessment
Yipsirimetee A; Chiewpoo P; Tripura R; Lek D; Day NPJ; Dondorp AM; Pukrittayakamee S; White NJ; Chotivanich K
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0148121. PubMed ID: 34978886
[TBL] [Abstract][Full Text] [Related]
7. Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum.
McCarthy JS; Abd-Rahman AN; Collins KA; Marquart L; Griffin P; Kümmel A; Fuchs A; Winnips C; Mishra V; Csermak-Renner K; Jain JP; Gandhi P
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199389
[TBL] [Abstract][Full Text] [Related]
8. Cell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated Antimalarials.
Dennis ASM; Lehane AM; Ridgway MC; Holleran JP; Kirk K
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555632
[TBL] [Abstract][Full Text] [Related]
9. Biochemical characterization and chemical inhibition of PfATP4-associated Na
Rosling JEO; Ridgway MC; Summers RL; Kirk K; Lehane AM
J Biol Chem; 2018 Aug; 293(34):13327-13337. PubMed ID: 29986883
[TBL] [Abstract][Full Text] [Related]
10. The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs.
Spillman NJ; Kirk K
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):149-62. PubMed ID: 26401486
[TBL] [Abstract][Full Text] [Related]
11. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Li R; Jain JP; Lefèvre G; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Oct; 58(10):6209-14. PubMed ID: 25114127
[TBL] [Abstract][Full Text] [Related]
12. Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor.
Goldgof GM; Durrant JD; Ottilie S; Vigil E; Allen KE; Gunawan F; Kostylev M; Henderson KA; Yang J; Schenken J; LaMonte GM; Manary MJ; Murao A; Nachon M; Murray R; Prescott M; McNamara CW; Slayman CW; Amaro RE; Suzuki Y; Winzeler EA
Sci Rep; 2016 Jun; 6():27806. PubMed ID: 27291296
[TBL] [Abstract][Full Text] [Related]
13. A G358S mutation in the Plasmodium falciparum Na
Qiu D; Pei JV; Rosling JEO; Thathy V; Li D; Xue Y; Tanner JD; Penington JS; Aw YTV; Aw JYH; Xu G; Tripathi AK; Gnadig NF; Yeo T; Fairhurst KJ; Stokes BH; Murithi JM; Kümpornsin K; Hasemer H; Dennis ASM; Ridgway MC; Schmitt EK; Straimer J; Papenfuss AT; Lee MCS; Corry B; Sinnis P; Fidock DA; van Dooren GG; Kirk K; Lehane AM
Nat Commun; 2022 Sep; 13(1):5746. PubMed ID: 36180431
[TBL] [Abstract][Full Text] [Related]
14. Metabolic responses in blood-stage malaria parasites associated with increased and decreased sensitivity to PfATP4 inhibitors.
Tewari SG; Elahi R; Kwan B; Rajaram K; Bhatnagar S; Reifman J; Prigge ST; Vaidya AB; Wallqvist A
Malar J; 2023 Feb; 22(1):56. PubMed ID: 36788578
[TBL] [Abstract][Full Text] [Related]
15. KAE609 (Cipargamin), a New Spiroindolone Agent for the Treatment of Malaria: Evaluation of the Absorption, Distribution, Metabolism, and Excretion of a Single Oral 300-mg Dose of [14C]KAE609 in Healthy Male Subjects.
Huskey SE; Zhu CQ; Fredenhagen A; Kühnöl J; Luneau A; Jian Z; Yang Z; Miao Z; Yang F; Jain JP; Sunkara G; Mangold JB; Stein DS
Drug Metab Dispos; 2016 May; 44(5):672-82. PubMed ID: 26921387
[TBL] [Abstract][Full Text] [Related]
16. Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine.
Stein DS; Jain JP; Kangas M; Lefèvre G; Machineni S; Griffin P; Lickliter J
Antimicrob Agents Chemother; 2015; 59(6):3493-500. PubMed ID: 25845867
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
[TBL] [Abstract][Full Text] [Related]
18. A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609.
Zhang R; Suwanarusk R; Malleret B; Cooke BM; Nosten F; Lau YL; Dao M; Lim CT; Renia L; Tan KS; Russell B
J Infect Dis; 2016 Jan; 213(1):100-4. PubMed ID: 26136472
[TBL] [Abstract][Full Text] [Related]
19. The early preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound.
Koller R; Mombo-Ngoma G; Grobusch MP
Expert Opin Investig Drugs; 2018 Oct; 27(10):803-810. PubMed ID: 30223692
[TBL] [Abstract][Full Text] [Related]
20. Alternatives to currently used antimalarial drugs: in search of a magic bullet.
Bhagavathula AS; Elnour AA; Shehab A
Infect Dis Poverty; 2016 Nov; 5(1):103. PubMed ID: 27809883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
